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surgical procedures among younger patients for the management of DD. METHODS: 
Using a nationwide commercial claims database, a retrospective cohort was identiﬁed 
who had undergone LC (n = 2095) or OC (n = 5971) between 4th quarter, 2005 
through 1st quarter, 2009. 2000 U.S. Census data was used to calculate age-adjusted 
temporal trends in the overall surgical procedure and logistic regression was used to 
determine the time trends in each surgical procedure, adjusting for age, gender, and 
the type of beneﬁt plan. RESULTS: A total of 8,066 surgical procedures were per-
formed during the study period (mean age = 53 ± 11, 55.7% Male). Quarterly mean 
number of surgical procedures(LC+OC) performed was 576 (SD = 39) and the annual 
mean number of LC+OC from 2006 to 2008 was 2297 (SD = 107). Quarterly age-
standardized surgical procedures(LC+OC) for DD declined by 9.26% for patients 
younger than 45, whereas overall surgical rate increased by 3.2% for older patients. 
The odds of having a LC over OC declined by 8% each consecutive quarter (95% CI 
0.91, 0.93) while controlling for other covariates. CONCLUSIONS: Data suggest that 
there was a slight decline over time in surgical procedures for younger patients. The 
reasons for the decline in surgical procedures for younger patients may be due to recent 
studies suggesting that DD is not more aggressive in younger patients as initially 
reported, and that the conservative medical treatment may be more appropriate with 
this population.
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OBJECTIVES: The National Health and Nutrition Examination Survey (NHANES) 
estimates chronic HCV infection prevalence at 1.3% of the US population or ∼3 
million individuals, with a peak HCV antibody prevalence of 4.3% for those born in 
the 1950s. From NHANES we can assume that 79.7% of HCV antibody positive 
patients will not clear the virus; therefore we expect to observe 3% chronic HCV 
infection in this peak population. METHODS: Patients diagnosed with HCV (ICD-9 
codes 070.41, 070.44, 070.51, 070.54, 070.70, 070.71, V02.61) between 2002 and 
2006 were identiﬁed in MedStat commercial health insurance claims. We calculated 
age-sex prevalence of diagnosis by birth year. A log-regression model was constructed 
to examine the relationship between prevalence of HCV diagnosis and number of 
observation years. RESULTS: The prevalence of patients with a HCV diagnosis in 
2006 was 0.12%. The prevalence of patients with HCV diagnosis was consistent in 
each year’s claims, peaking in those born between 1950–1955. Longitudinal data 
across ﬁve years demonstrated increasing diagnosis rates with additional years of 
observation, according to a log function. Modeled for 10 years of observation, total 
diagnosed prevalence was estimated at 0.29% (R2 = 0.99); peak prevalence was 
1.35% for males and 0.64% for females for those born in the early 1950s. CONCLU-
SIONS: In each year examined, the claims-based prevalence of an HCV diagnosis was 
about 10% of the NHANES estimated prevalence (0.12% vs. 1.3%). Although diag-
nosed HCV prevalence increased with years of observation, the 10-year modeled 
diagnosis prevalence was only 22% of NHANES estimated prevalence. Like in 
NHANES, peak prevalence of HCV in claims was observed in patients born in the 
1950s. This suggests that many patients have long-standing HCV infection and are at 
possible risk of decompensation. Further research is warranted to examine whether 
HCV-related advanced liver disease is more commonly coded in claims data.
GASTROINTESTINAL DISORDERS – Cost Studies
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OBJECTIVES: Low persistency for oral 5-ASA drugs is associated with increased risk 
of relapse of ulcerative colitis(UC) and subsequent costs. We constructed a one-year 
budget impact model to compare annual all-cause direct incremental costs(IC) of 
treatment for the health plan(HP) per mild-to-moderate UC patient using oral 5-ASA 
drugs and associated persistency rates(PRs). METHODS: Assuming a budget holder’s 
perspective for a one-year horizon, the model analyzed the impact of PR on total UC 
related all-cause direct IC. PRs for 5-ASA drugs(mesalamine CR[CRM] 250mg 7% 
& 500mg 10%, balsalazide disodium[BD] 10%, olsalazine[OLS] 10%, mesalamine 
DR[DRM] 9%, multi matrix system mesalamine[MMX] 20%) were derived from 
published literature. UC patients within the HP were distributed to drugs based on 
September 2009 market share data and classiﬁed as persistent if they reﬁlled within a 
timeframe of up to twice the duration of their prescription. Annual UC-related phar-
macy costs were calculated using net wholesale acquisition cost, and additional all-
cause direct ICs for patients with/without relapse were cited from published literature. 
Sensitivity analyses varying net drug costs and PRs were performed to determine 
impact on health care costs. RESULTS: Average annual all-cause UC costs per patient 
were: $13,135 CRM-250; $13,065 CRM-500; $12,914 BD; $12,804 OLS, $12,688 
DRM; $12,255 MMX. Inpatient costs were lower for MMX($5,667) as compared to 
market leader(DRM;$6,216) and lowest priced drug alternative(OLS;$6,343). Sensi-
tivity analyses indicated higher savings/patient for MMX than DRM($462 vs. $30, 
respectively). The primary driver for inpatient cost differences was the frequency of 
relapse reduced by persistency. A health plan with 1 million covered lives(2,300 UC 
patients) can save $401,000($0.03 per member/month) by switching 50% of UC 
patients to MMX. CONCLUSIONS: This analysis illustrates the impact of medication 
persistence on reduction of UC relapse and associated health care costs. Health plans 
may achieve savings by including drugs with high PRs in their formulary.
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OBJECTIVES: Colectomy is a standard procedure in complicated colonic diverticular 
disease (DD) including diverticulosis and diverticulitis. Although laparoscopic colec-
tomy (LC) has demonstrated some clinical advantages over open colectomy (OC), the 
true ﬁnancial burden, cost and reimbursement structures between the two surgical 
procedures remain unclear. The purpose of this study was to compare patient ﬁnancial 
burden, direct surgical costs and reimbursements for OC and LC procedures in DD. 
METHODS: Nationwide commercial claims database from 2003 through 2007 was 
used to identify 1,614 patients who had undergone OC (n = 1327) or LC (n = 287) 
for DD. Patient ﬁnancial burden (deﬁned by out-of-pocket [OOP] costs including 
co-pay, deductible and coinsurance), direct surgical costs, reimbursements and cost-
to-charge ratios for OC and LC were compared using the Student’s t-test and chi-
square test where appropriate. RESULTS: OC and LC groups differed with respect 
to mean age (60 and 64 years, respectively; p < 0.001) but did not differ in male/
female ratio. OOP costs were signiﬁcantly greater for OC ($410 vs. $350 for LC; p 
< 0.001). Both surgical costs and the reimbursements per case were signiﬁcantly less 
for OC ($4231 ± 98 and $1412 ± 35, respectively) than LC ($5246 ± 231 and $1809 
± 80 respectively; both p < 0.001). Cost-to-charge ratios were the same for both surgi-
cal procedures (0.38). CONCLUSIONS: This analysis demonstrated that patient 
ﬁnancial burden, as assessed by OOP costs, was moderately greater for open colec-
tomy, but the direct costs and reimbursements of OC were signiﬁcantly lower than 
LC. However, low surgical costs may be offset by potential increases in length of 
hospital stay due to longer recovery time for OC. Understanding differences in cost 
structures may be helpful in further investigations of the cost-effectiveness of these 
two surgical procedures in diverticular disease.
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OBJECTIVES: Crohn’s Disease (CD) and Ulcerative Colitis (UC), collectively termed 
Inﬂammatory Bowel Disease (IBD), are associated with hospitalizations, surgical pro-
cedures, and long-term medical follow up. The objectives of the current study were 
to quantify the national pediatric IBD burden in 2006 and stratify by demographics 
by determining the (1) number of hospitalizations; (2) number of days spent in the 
hospital; and (3) hospitalization costs. METHODS: The 2006 Kids’ Inpatient Data-
base was used to examine IBD in hospitalized children and adolescents 20 years and 
younger with a primary diagnosis of either CD or UC. Frequency of discharges, the 
total and mean length of stay (LOS) and costs were calculated, and stratiﬁed by various 
patient and hospital characteristics such as age, gender, expected primary payer, 
patient income, surgery status, teaching status, hospital size, location and region. 
RESULTS: In 2006, there were 10,777 IBD-related pediatric visits, of which 6,599 
were due to CD and 4,178 were due to UC. For CD and UC, respectively, there were 
37,175 and 27,810 days spent in the hospital; mean LOS was 5.63 and 6.66 days. 
The total and mean costs for CD were $66.3 million and $10,176, respectively. The 
total and mean costs for UC were $48.6 million and $11,836, respectively. For CD, 
0–5 year old patients had the highest mean LOS (8.10 days) and mean cost ($13,894), 
while, for UC, 11–15-year old patients had the highest mean LOS (7.49 days) and 
mean cost ($13,407). Patients with Medicaid had a higher mean LOS and cost than 
those with private insurance. Surgery increased mean LOS over 3 days and almost 
doubled the cost for IBD hospitalizations. CONCLUSIONS: IBD is a burdensome 
illness. Future research will determine if newer treatment options can reduce 
hospitalizations.
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OBJECTIVES: Functional dyspepsia is a common, morbid condition but data are 
limited on the indirect and direct costs for employees with functional dyspepsia or on 
its impact on productivity. Few data on absenteeism no objective information are 
available. This study aimed to assess functional dyspepsia’s incremental health beneﬁt 
costs and effects on absenteeism and work output (productivity). METHODS: We 
performed a retrospective analysis of payroll data and adjudicated health insurance 
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medical and prescription claims collected over a 4-year study period (January 1, 
2001–December 31, 2004) from more than 300,000 employees. Data from employees 
with and without (controls) functional dyspepsia were compared using 2-part regres-
sion techniques. Outcome measures included direct and indirect costs paid by the 
employer, absenteeism, direct costs by the place of service where care was performed, 
and objectively measured productivity output. RESULTS: Employees with functional 
dyspepsia (N = 1669) had greater average annual direct medical and prescription drug 
costs and indirect costs (due to sick leave, short- and long-term disability absences) 
than controls (N = 274,206). Compared with controls, the functional dyspepsia 
employees incurred health beneﬁt costs that were $5,138 greater and had greater costs 
for each place of service (all P < 0.0001). The employees with functional dyspepsia 
had an additional 0.83 absence days per year and produced 12% fewer units per hour 
than controls (both P < 0.05). CONCLUSIONS: Employees with functional dyspepsia 
have greater costs at all places of service and lower productivity than employees 
without functional dyspepsia.
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OBJECTIVES: The aim of this study was to estimate the annual societal disease 
burden of irritable bowel syndrome (IBS) in Korea for the year of 2008. METHODS: 
The claim data with IBS were extracted from the Health Insurance Review & Assess-
ment Service database in 2008 of Korea. After deﬁnition of patient with specialists, 
the prevalence and medical costs were calculated. The number of outpatient visits and 
length of hospital stay also were calculated to estimate transportation cost and pro-
ductivity loss. RESULTS: The annual national patients with IBS were estimated to 
1.30 million with 753,688 (57.79%) for female. The results showed that the 
crude prevalence of IBS was 2.68% (95%CI: 2.66%-2.71%, 2.25% for male and 
3.12% for female) in 2008. The total cost due to IBS was 14.9 billion won (1$ = 
1047.30 won, 2008) including 348 million won for direct medical cost (2.33%), 88 
million won for nonmedical cost (transportation costs), and 14.5 billion won for lost 
work due to illness. CONCLUSIONS: The disease burden of IBS appears to be high 
because of the high morbidity although not a signiﬁcant cause of death. The result is 
likely to underestimate due to using claim data and strict deﬁnition of patient. 
However, this data might be useful and necessary to support evidence based decision 
making for IBS.
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OBJECTIVES: To compare direct and indirect costs between HCV patients on 
pegylated interferon with ribavirin (PEG-RBV), untreated HCV, and non-HCV con-
trols. METHODS: We identiﬁed three cohorts using the MarketScan Commercial 
Claims and Encounters Database® from 2002–2007: HCV patients on PEG-RBV, 
untreated HCV, and non-HCV controls. We used propensity scores to match treated 
to untreated (1:1), and HCV to non-HCV patients (1:3). We compared direct costs 
and utilization across the cohorts. We performed subset analysis using the MarketScan 
Health and Productivity Management Database® to evaluate absenteeism and short-
term disability costs. RESULTS: We identiﬁed 10,001 PEG-RBV patients. Compared 
to untreated patients, treated patients had higher total medical costs ($28,547 vs. 
$21,752; p < 0.001) outpatient pharmacy costs ($17,419 vs. $2,900; p < 0.001) and 
outpatient physician visit costs ($894 vs. $787; p < 0.001), but lower inpatient costs 
($3,942 vs. $9,543; p < 0.001) and ER costs ($366 vs. $505; p < 0.001). Treated 
patients had similar absenteeism rates (93% vs. 88%; p = 0.27), higher short-term 
disability rates (33% vs. 30%;p < 0.001) and higher indirect costs ($11,528 vs. 
$9,316; p < 0.05). Non-HCV controls had signiﬁcantly lower costs in all categories 
compared to patients with HCV. Total costs among matched non-HCV costs were 
$15,932, outpatient pharmacy costs were $1,796, outpatient physician visit costs were 
$429, inpatient costs were $2,181, and ER costs were $184; indirect costs were 
$7,654. After adjusting for demographic and clinical characteristics, including HIV 
and cirrhosis, differences remained signiﬁcant but diminished. CONCLUSIONS: HCV 
patients engender a higher economic burden compared to non-HCV controls. Treated 
patients cost more than untreated patients; the cost differential is primarily driven by 
higher outpatient pharmacy costs. Indirect cost differences are driven by greater 
absenteeism duration and greater short term disability use and duration. These data 
provide insight into the economic burden of HCV and its treatment, and may be 
employed in future health economic analyses evaluating existing and emerging 
therapies.
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OBJECTIVES: To document variations in resource utilization and costs by disease 
severity, sustained viral response (SVR), and genotype in a European population with 
chronic hepatitis C virus (C-HCV). METHODS: Patient charts from the UK, France, 
Germany, Spain, and Italy were retrospectively reviewed. Inclusion criteria were: 
C-HCV diagnosis within past 5 years; age ≥18 years; no diagnoses of hepatitis B or 
HIV/AIDS; ≥1 year follow-up post-diagnosis; no clinical trial participation. All-cause 
utilization and costs (2009 3) for hospitalizations, emergency room (ER) and ofﬁce 
visits, and specialty referrals were aggregated within patients over 1 year post-diag-
nosis. C-HCV severity was assessed via Metavir score. Among patients receiving 
C-HCV-directed pharmacotherapy, SVR was deﬁned by viral RNA < 10 IU/mL at ≥6 
months post-treatment. Utilization and cost differences across clinical factors were 
assessed with multivariate modeling. RESULTS: In total, 1016 patients were identi-
ﬁed. Overall, 23% of severe patients were hospitalized versus 2.5% of mild. Hospi-
talization was 5 times more likely in severe C-HCV compared to mild (odds ratio 
[OR] = 5.39; P = 0.008), while the hospitalization rate, measured by Poisson incidence 
rate ratio (IRR), was 4 times higher (IRR = 3.98; P = 0.010). Hospital costs were 
31380 higher in severe versus mild disease (P = 0.001). Hospitalization risk in SVR 
attainers was less than half that of non-attainers (OR = 0.22; P < 0.0001). ER, ofﬁce, 
and specialist visit rates were signiﬁcantly lower among SVR attainers. Genotype had 
little effect on utilization, but genotype 1 was associated with slightly lower (390 per 
patient; P < 0.0001) hospital costs versus genotypes ≥2. CONCLUSIONS: Disease 
severity and SVR are important predictors of C-HCV costs. Awareness of these factors 
by public health systems, which bear the high cost burden of C-HCV, may help 
promote strategies for earlier disease detection and increased treatment initiation 
before progression occurs, as well as formulary access for more convenient therapies 
that increase treatment persistence and thereby SVR rates.
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OBJECTIVES: Assess patterns of utilization and costs of twice daily 24 mcg dosing 
of lubiprostone in a large managed care population. METHODS: Patients included 
Humana members 18 years and older with medical claims for chronic constipation 
(CC) and/or irritable bowel syndrome (IBS) between April 1, 2006 and April 30, 2008. 
The index date was the ﬁrst diagnosis of CC or IBS. Patients had at least 180-days of 
continuous enrollment pre-index and at least 30-days post-index. Users and non-users 
were compared. Users were compared pre- and post-lubiprostone initiation. RESULTS: 
A total of 92,804 patients with a diagnosis of CC or IBS were identiﬁed during the 
study period; 1873 ﬁlled at least one 30-day prescription for lubiprostone. Seventy-ﬁve 
percent of users were female. Lubiprostone users were younger than non-users (61.6 
vs. 66.2 yrs old) and more likely to be co-prescribed opiates (35.5 vs. 29.4%), anti-
histamines (14.8 vs. 9.5%) and tricyclic antidepressants (8.1 vs. 4.7%), all statistically 
signiﬁcant. Common co-morbidities in lubiprostone users were back problems 
(23.6%) and abdominal pain (21.9%). A total of 1605 users had both 6-months pre- 
and post-lubiprostone initiation data. A total of 42.2% of these patients ﬁlled more 
than one 30-day lubiprostone prescription; 6.42% ﬁlled 6 or more. Usage of other 
prescription laxatives decreased by 4.6% (p < 0.05) subsequent to lubiprostone initia-
tion. Monthly health care costs per utilizing member increased by $67.10 (p < 0.0001). 
Pharmacy costs rose by $71.73 (p < 0.0001) and ER costs decreased by $8.12 (p < 
0.05). Pre-post changes in outpatient and inpatient costs were not signiﬁcant. Monthly 
inpatient and ER visits for these 1605 members decreased by 0.31 and 0.08 per utiliz-
ing member respectively (p < 0.05) in the 6-months after starting lubiprostone. 
Changes in outpatient visits were not signiﬁcant. CONCLUSIONS: Lubiprostone 
users were younger females who were co-prescribed opiates and had back problems. 
Higher health care costs were offset by a decrease in ER costs.
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Hepatitis C affects approximately 180 million people worldwide and is one of the 
main causes of chronic liver disease. HCV infection progresses to chronicity in approx-
imately 80% of infected individuals, from whom up to 20% can develop cirrhosis 
over 20 years, thus presenting high risk of complications related to hepatic insufﬁ-
ciency and/or hepatocellular carcinoma. OBJECTIVES: To compare treatment costs 
and outcomes of peginterferon-alfa-2a versus peginterferon-alfa-2b, both associated 
